 Kathryn Colborn
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 9 | 2022 | 724 | 3.210 |
Why?
| | Postoperative Complications | 21 | 2023 | 2113 | 2.230 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 126 | 1.540 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 174 | 1.480 |
Why?
| | Machine Learning | 6 | 2022 | 271 | 1.360 |
Why?
| | Quality Improvement | 11 | 2023 | 940 | 1.350 |
Why?
| | Malaria | 4 | 2023 | 50 | 1.280 |
Why?
| | Models, Statistical | 4 | 2020 | 656 | 0.900 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 27 | 0.890 |
Why?
| | Sepsis | 5 | 2022 | 491 | 0.890 |
Why?
| | Postoperative Hemorrhage | 1 | 2022 | 79 | 0.870 |
Why?
| | Artificial Intelligence | 1 | 2023 | 130 | 0.870 |
Why?
| | Surgical Wound Infection | 4 | 2022 | 216 | 0.850 |
Why?
| | Plasmodium vivax | 2 | 2018 | 4 | 0.810 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.810 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.670 |
Why?
| | Poisson Distribution | 1 | 2018 | 75 | 0.670 |
Why?
| | Health Plan Implementation | 1 | 2019 | 125 | 0.660 |
Why?
| | Hospitalization | 6 | 2021 | 1774 | 0.630 |
Why?
| | Retrospective Studies | 29 | 2023 | 12331 | 0.630 |
Why?
| | Humans | 86 | 2023 | 117633 | 0.630 |
Why?
| | Mosquito Control | 2 | 2023 | 18 | 0.620 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.570 |
Why?
| | Anopheles | 1 | 2015 | 12 | 0.560 |
Why?
| | Risk Assessment | 13 | 2023 | 3208 | 0.560 |
Why?
| | Shock, Septic | 3 | 2022 | 196 | 0.550 |
Why?
| | Pancreatic Neoplasms | 4 | 2023 | 755 | 0.540 |
Why?
| | Drug Prescriptions | 3 | 2021 | 264 | 0.520 |
Why?
| | Databases, Factual | 9 | 2022 | 1145 | 0.520 |
Why?
| | Middle Aged | 28 | 2023 | 28659 | 0.470 |
Why?
| | Patient Discharge | 2 | 2020 | 820 | 0.460 |
Why?
| | Hospital Mortality | 1 | 2016 | 853 | 0.440 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 357 | 0.430 |
Why?
| | Primary Health Care | 2 | 2019 | 1573 | 0.420 |
Why?
| | Risk Factors | 19 | 2023 | 9124 | 0.420 |
Why?
| | Algorithms | 4 | 2019 | 1550 | 0.420 |
Why?
| | Aged | 21 | 2023 | 20249 | 0.410 |
Why?
| | Influenza, Human | 3 | 2021 | 535 | 0.400 |
Why?
| | Adult | 25 | 2023 | 32118 | 0.390 |
Why?
| | Female | 38 | 2023 | 63247 | 0.390 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2023 | 208 | 0.380 |
Why?
| | Emergency Treatment | 2 | 2021 | 114 | 0.370 |
Why?
| | Male | 36 | 2023 | 60403 | 0.370 |
Why?
| | Palliative Care | 4 | 2022 | 638 | 0.360 |
Why?
| | Surgeons | 2 | 2023 | 204 | 0.360 |
Why?
| | Inpatients | 2 | 2022 | 359 | 0.360 |
Why?
| | Child, Preschool | 12 | 2023 | 9714 | 0.340 |
Why?
| | Hospitals | 3 | 2022 | 540 | 0.340 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 202 | 0.340 |
Why?
| | Research Design | 3 | 2022 | 968 | 0.330 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 112 | 0.320 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 235 | 0.320 |
Why?
| | Incidence | 6 | 2020 | 2504 | 0.310 |
Why?
| | Chagas Disease | 2 | 2018 | 31 | 0.310 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.310 |
Why?
| | Neoadjuvant Therapy | 4 | 2023 | 312 | 0.300 |
Why?
| | Colorado | 7 | 2021 | 4401 | 0.290 |
Why?
| | Asthma | 1 | 2019 | 2016 | 0.290 |
Why?
| | Patient Reported Outcome Measures | 3 | 2022 | 233 | 0.290 |
Why?
| | Cohort Studies | 9 | 2023 | 5112 | 0.280 |
Why?
| | Heart Failure | 4 | 2018 | 2029 | 0.270 |
Why?
| | Emergency Service, Hospital | 3 | 2020 | 1819 | 0.260 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 759 | 0.250 |
Why?
| | United States | 14 | 2023 | 12768 | 0.250 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6795 | 0.250 |
Why?
| | Specialties, Surgical | 2 | 2021 | 70 | 0.240 |
Why?
| | Young Adult | 11 | 2020 | 11077 | 0.240 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1971 | 0.240 |
Why?
| | Insecticides | 1 | 2023 | 36 | 0.230 |
Why?
| | Risk Adjustment | 1 | 2023 | 68 | 0.230 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 58 | 0.230 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2022 | 47 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1228 | 0.230 |
Why?
| | Pain, Postoperative | 2 | 2021 | 184 | 0.230 |
Why?
| | Polypharmacy | 1 | 2023 | 74 | 0.230 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 41 | 0.230 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 76 | 0.220 |
Why?
| | Adolescent | 13 | 2023 | 18902 | 0.220 |
Why?
| | Galectins | 1 | 2022 | 20 | 0.220 |
Why?
| | Medication Therapy Management | 1 | 2023 | 78 | 0.220 |
Why?
| | Delirium | 1 | 2023 | 70 | 0.220 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 86 | 0.220 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 37 | 0.220 |
Why?
| | Mozambique | 2 | 2018 | 5 | 0.220 |
Why?
| | Ivermectin | 1 | 2021 | 10 | 0.220 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2022 | 58 | 0.210 |
Why?
| | Preoperative Care | 2 | 2021 | 323 | 0.210 |
Why?
| | Knee Joint | 2 | 2021 | 329 | 0.210 |
Why?
| | Mastectomy, Segmental | 1 | 2021 | 88 | 0.210 |
Why?
| | Dysbiosis | 1 | 2022 | 136 | 0.210 |
Why?
| | Oxycodone | 1 | 2021 | 48 | 0.200 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.200 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 18 | 0.200 |
Why?
| | Program Evaluation | 3 | 2021 | 870 | 0.200 |
Why?
| | Gastric Bypass | 1 | 2022 | 99 | 0.200 |
Why?
| | Arthroplasty | 1 | 2020 | 50 | 0.200 |
Why?
| | Faculty | 1 | 2021 | 119 | 0.200 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 48 | 0.200 |
Why?
| | Artemisinins | 1 | 2019 | 3 | 0.190 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 206 | 0.190 |
Why?
| | Antimalarials | 1 | 2019 | 24 | 0.190 |
Why?
| | Prisons | 1 | 2010 | 50 | 0.190 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 268 | 0.180 |
Why?
| | Waiting Lists | 2 | 2021 | 210 | 0.180 |
Why?
| | Outpatients | 1 | 2022 | 287 | 0.180 |
Why?
| | Burns | 1 | 2022 | 225 | 0.180 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 128 | 0.180 |
Why?
| | Rural Population | 2 | 2020 | 464 | 0.180 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 65 | 0.180 |
Why?
| | General Surgery | 1 | 2021 | 140 | 0.180 |
Why?
| | Hypersensitivity | 1 | 2023 | 289 | 0.180 |
Why?
| | Organ Transplantation | 1 | 2021 | 179 | 0.180 |
Why?
| | Obesity, Morbid | 1 | 2022 | 184 | 0.180 |
Why?
| | Breast Neoplasms | 2 | 2021 | 1929 | 0.180 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 56 | 0.180 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 227 | 0.180 |
Why?
| | Aftercare | 1 | 2020 | 191 | 0.180 |
Why?
| | Condoms, Female | 1 | 2008 | 6 | 0.180 |
Why?
| | Zebrafish | 1 | 2022 | 413 | 0.170 |
Why?
| | Reproductive Medicine | 1 | 2008 | 12 | 0.170 |
Why?
| | Autistic Disorder | 1 | 2020 | 161 | 0.170 |
Why?
| | Datasets as Topic | 1 | 2019 | 98 | 0.170 |
Why?
| | Social Marketing | 1 | 2008 | 15 | 0.170 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 189 | 0.170 |
Why?
| | Community Participation | 1 | 2019 | 120 | 0.170 |
Why?
| | Triage | 1 | 2021 | 210 | 0.170 |
Why?
| | Quinolines | 1 | 2019 | 135 | 0.170 |
Why?
| | Ventricular Function | 1 | 2018 | 63 | 0.170 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 148 | 0.170 |
Why?
| | Developed Countries | 1 | 2018 | 40 | 0.170 |
Why?
| | Hospitals, University | 1 | 2018 | 189 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 81 | 0.170 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 42 | 0.170 |
Why?
| | Computers, Handheld | 1 | 2018 | 28 | 0.170 |
Why?
| | Climate | 1 | 2018 | 90 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 397 | 0.170 |
Why?
| | Patient Admission | 1 | 2019 | 199 | 0.170 |
Why?
| | Population Groups | 1 | 2018 | 55 | 0.170 |
Why?
| | ROC Curve | 1 | 2019 | 499 | 0.170 |
Why?
| | Intensive Care Units | 1 | 2022 | 594 | 0.170 |
Why?
| | Infant | 7 | 2019 | 8255 | 0.170 |
Why?
| | Immunoglobulin A | 1 | 2019 | 171 | 0.170 |
Why?
| | Geography | 1 | 2018 | 179 | 0.160 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 41 | 0.160 |
Why?
| | Child | 10 | 2023 | 18649 | 0.160 |
Why?
| | Safety-net Providers | 1 | 2019 | 109 | 0.160 |
Why?
| | Recovery of Function | 1 | 2021 | 607 | 0.160 |
Why?
| | Occupational Health | 1 | 2010 | 207 | 0.160 |
Why?
| | Epidemics | 1 | 2018 | 66 | 0.160 |
Why?
| | Condoms | 1 | 2008 | 126 | 0.160 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 113 | 0.160 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 312 | 0.160 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 408 | 0.160 |
Why?
| | Patient Compliance | 1 | 2021 | 588 | 0.160 |
Why?
| | Anxiety Disorders | 1 | 2010 | 315 | 0.160 |
Why?
| | Gastroenteritis | 1 | 2017 | 65 | 0.160 |
Why?
| | Occupational Exposure | 1 | 2010 | 314 | 0.150 |
Why?
| | Students, Medical | 1 | 2021 | 307 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2021 | 475 | 0.150 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 453 | 0.150 |
Why?
| | Cell Phone | 1 | 2017 | 79 | 0.150 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 67 | 0.150 |
Why?
| | Nurse Practitioners | 1 | 2018 | 117 | 0.150 |
Why?
| | Adenocarcinoma | 1 | 2023 | 818 | 0.150 |
Why?
| | Alcoholism | 1 | 2023 | 797 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2020 | 310 | 0.150 |
Why?
| | Fever | 1 | 2017 | 300 | 0.150 |
Why?
| | Morbidity | 3 | 2022 | 262 | 0.150 |
Why?
| | Cannabidiol | 1 | 2016 | 55 | 0.150 |
Why?
| | Mass Screening | 2 | 2020 | 1081 | 0.150 |
Why?
| | Patient Readmission | 2 | 2020 | 659 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 119 | 0.140 |
Why?
| | Forecasting | 1 | 2018 | 371 | 0.140 |
Why?
| | Melanoma | 1 | 2022 | 703 | 0.140 |
Why?
| | Healthcare Disparities | 2 | 2018 | 490 | 0.140 |
Why?
| | Models, Organizational | 1 | 2016 | 152 | 0.140 |
Why?
| | Humidity | 1 | 2015 | 40 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2019 | 535 | 0.140 |
Why?
| | Quality of Life | 4 | 2023 | 2354 | 0.140 |
Why?
| | Mobile Applications | 1 | 2017 | 147 | 0.140 |
Why?
| | Prognosis | 5 | 2022 | 3549 | 0.140 |
Why?
| | Advance Care Planning | 1 | 2018 | 187 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2022 | 812 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 395 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2016 | 188 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2023 | 9353 | 0.130 |
Why?
| | Emergency Medical Services | 1 | 2021 | 541 | 0.130 |
Why?
| | Massage | 2 | 2010 | 47 | 0.130 |
Why?
| | Chronic Pain | 1 | 2018 | 214 | 0.130 |
Why?
| | Pain | 1 | 2010 | 796 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2018 | 401 | 0.130 |
Why?
| | Parasitemia | 1 | 2013 | 9 | 0.130 |
Why?
| | Software | 1 | 2018 | 532 | 0.130 |
Why?
| | Family Practice | 1 | 2018 | 479 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 721 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1897 | 0.120 |
Why?
| | Indians, North American | 1 | 2009 | 561 | 0.120 |
Why?
| | Models, Biological | 1 | 2021 | 1763 | 0.120 |
Why?
| | Research | 1 | 2016 | 445 | 0.120 |
Why?
| | Medicaid | 1 | 2017 | 404 | 0.120 |
Why?
| | Epilepsy | 1 | 2016 | 278 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1152 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 470 | 0.110 |
Why?
| | Temperature | 1 | 2015 | 616 | 0.110 |
Why?
| | Feedback | 2 | 2023 | 153 | 0.110 |
Why?
| | Pain Management | 2 | 2010 | 300 | 0.110 |
Why?
| | Prevalence | 3 | 2023 | 2438 | 0.110 |
Why?
| | Uganda | 2 | 2023 | 84 | 0.110 |
Why?
| | Logistic Models | 3 | 2023 | 2018 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2541 | 0.100 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2022 | 117 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2017 | 745 | 0.100 |
Why?
| | Internship and Residency | 1 | 2021 | 1026 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 3223 | 0.100 |
Why?
| | Lymph Node Excision | 2 | 2022 | 154 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1404 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2884 | 0.100 |
Why?
| | Postoperative Period | 2 | 2021 | 307 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 681 | 0.100 |
Why?
| | Laboratories | 2 | 2021 | 97 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2016 | 0.100 |
Why?
| | Feeding Behavior | 1 | 2015 | 556 | 0.100 |
Why?
| | Prospective Studies | 4 | 2022 | 6422 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2016 | 814 | 0.090 |
Why?
| | Seasons | 2 | 2020 | 436 | 0.090 |
Why?
| | Immunization Programs | 1 | 2009 | 197 | 0.080 |
Why?
| | Comorbidity | 2 | 2022 | 1650 | 0.080 |
Why?
| | Diarrhea | 2 | 2019 | 172 | 0.080 |
Why?
| | Urban Population | 2 | 2020 | 421 | 0.080 |
Why?
| | School Health Services | 1 | 2009 | 189 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4911 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1209 | 0.070 |
Why?
| | Insurance Coverage | 2 | 2017 | 219 | 0.070 |
Why?
| | Affect | 1 | 2008 | 264 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 617 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4630 | 0.070 |
Why?
| | Body Mass Index | 2 | 2023 | 2076 | 0.070 |
Why?
| | Pneumonia | 2 | 2020 | 578 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1163 | 0.070 |
Why?
| | Acute Disease | 2 | 2017 | 983 | 0.060 |
Why?
| | Cytokines | 2 | 2023 | 1951 | 0.060 |
Why?
| | Pandemics | 2 | 2021 | 1155 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 4842 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2010 | 569 | 0.060 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1422 | 0.060 |
Why?
| | Biological Variation, Population | 1 | 2022 | 22 | 0.060 |
Why?
| | Burn Units | 1 | 2022 | 24 | 0.060 |
Why?
| | Papua New Guinea | 1 | 2012 | 7 | 0.060 |
Why?
| | Body Surface Area | 1 | 2022 | 30 | 0.060 |
Why?
| | Patient Acuity | 1 | 2022 | 38 | 0.060 |
Why?
| | HIV Infections | 1 | 2016 | 2512 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2023 | 342 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 99 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 148 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 49 | 0.050 |
Why?
| | Gastrectomy | 1 | 2022 | 78 | 0.050 |
Why?
| | Demography | 1 | 2022 | 279 | 0.050 |
Why?
| | Mastectomy | 1 | 2021 | 111 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 520 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 130 | 0.050 |
Why?
| | Habits | 1 | 2020 | 43 | 0.050 |
Why?
| | Preoperative Period | 1 | 2021 | 103 | 0.050 |
Why?
| | Axilla | 1 | 2020 | 58 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 196 | 0.050 |
Why?
| | Censuses | 1 | 2020 | 21 | 0.050 |
Why?
| | Research Personnel | 1 | 2022 | 157 | 0.050 |
Why?
| | South Africa | 1 | 2021 | 155 | 0.050 |
Why?
| | Reoperation | 1 | 2023 | 554 | 0.050 |
Why?
| | Policy | 1 | 2021 | 111 | 0.050 |
Why?
| | Schools, Medical | 1 | 2021 | 153 | 0.050 |
Why?
| | Animals | 3 | 2022 | 34350 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 303 | 0.050 |
Why?
| | Emergencies | 1 | 2021 | 165 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 146 | 0.050 |
Why?
| | Blood Proteins | 1 | 2022 | 247 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2021 | 476 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 34 | 0.050 |
Why?
| | Mentors | 1 | 2021 | 156 | 0.050 |
Why?
| | Urination Disorders | 1 | 2019 | 13 | 0.050 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 10 | 0.050 |
Why?
| | Leucovorin | 1 | 2019 | 47 | 0.050 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 42 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2020 | 253 | 0.050 |
Why?
| | Program Development | 1 | 2021 | 372 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 85 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 305 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 566 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2023 | 1584 | 0.040 |
Why?
| | Risk | 1 | 2022 | 926 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 495 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 150 | 0.040 |
Why?
| | Washington | 1 | 2008 | 129 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 303 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 34 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 528 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 142 | 0.040 |
Why?
| | Time Factors | 2 | 2021 | 6906 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 116 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 281 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 153 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 208 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 385 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2020 | 463 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 5230 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 317 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 505 | 0.040 |
Why?
| | Prisoners | 1 | 2008 | 88 | 0.040 |
Why?
| | Proctitis | 1 | 2016 | 4 | 0.040 |
Why?
| | Viral Load | 1 | 2019 | 416 | 0.040 |
Why?
| | Odds Ratio | 1 | 2010 | 1038 | 0.040 |
Why?
| | Urogenital System | 1 | 2016 | 13 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2018 | 263 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1807 | 0.040 |
Why?
| | Latin America | 1 | 2016 | 70 | 0.040 |
Why?
| | Guatemala | 1 | 2017 | 290 | 0.040 |
Why?
| | Weight Loss | 1 | 2022 | 711 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2021 | 595 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 245 | 0.040 |
Why?
| | Population Surveillance | 1 | 2019 | 449 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2017 | 134 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2020 | 671 | 0.040 |
Why?
| | Length of Stay | 1 | 2020 | 1046 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2010 | 538 | 0.040 |
Why?
| | Radiation Injuries | 1 | 2016 | 137 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 791 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 347 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1019 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1199 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 444 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 169 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 227 | 0.030 |
Why?
| | Echocardiography | 1 | 2018 | 616 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 605 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2139 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 886 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 650 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 265 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 2875 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 786 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 896 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 871 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1623 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1143 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1441 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2948 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3269 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1918 | 0.030 |
Why?
| | Communication | 1 | 2018 | 731 | 0.030 |
Why?
| | Health Promotion | 1 | 2008 | 682 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1524 | 0.030 |
Why?
| | Biomarkers | 1 | 2022 | 3574 | 0.030 |
Why?
| | Inflammation | 1 | 2022 | 2538 | 0.030 |
Why?
| | Registries | 1 | 2018 | 1969 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2711 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 989 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 282 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 798 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|